Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cetirizine hydrochloride pseudo ephedrine sustained-release pellet and preparation method thereof

A technology of cetirizine hydrochloride and pseudoephedrine hydrochloride, applied in the field of cetirizine hydrochloride-pseudoephedrine hydrochloride sustained-release pellets and the preparation field thereof, can solve the problems such as inability to cure rhinitis, recurrence, etc. Reduce irritating effects

Inactive Publication Date: 2015-04-08
HARBIN SHENGJI PHARMA
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] There are many drugs for treating rhinitis on the market, but most of them cannot cure rhinitis and often relapse

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cetirizine hydrochloride pseudo ephedrine sustained-release pellet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] A kind of cetirizine hydrochloride pseudoephedrine sustained-release pellets, comprising drug-containing pellets and a coating layer, the coating layer wraps drug-containing pellets, and the drug-containing pellets include: 5mg cetirizine hydrochloride, 125mg pseudoephedrine hydrochloride, 80mg blank ball core, 100-200mg filler, 25-125mg lubricant, 5-50mg binder, and the coating layer includes: 45-225mg Eudragit NE30D, 14-68mg talc powder.

[0034] The optimal mass ratio of raw materials in the drug-containing pellets is: 5 mg of cetirizine hydrochloride, 125 mg of pseudoephedrine hydrochloride, 80 mg of blank core, 190 mg of filler, 40 mg of lubricant, and 10 mg of binder.

[0035] The optimal mass ratio of raw materials in the coating layer is: 105mg Eudragit NE30D, 24mg talcum powder.

[0036] The filler is microcrystalline cellulose.

[0037] Described lubricant is talcum powder.

[0038] The binder is hypromellose.

[0039] The coating layer also i...

Embodiment 2

[0041] A preparation method of cetirizine hydrochloride pseudoephedrine sustained-release pellets, comprising the following steps:

[0042] Step 1: material preparation: according to the above mass ratio, cetirizine hydrochloride and pseudoephedrine hydrochloride are pulverized with a pulverizer respectively, and passed through a 100-mesh sieve;

[0043] Step 2: Mixing: Weigh cetirizine hydrochloride, pseudoephedrine hydrochloride, and microcrystalline cellulose according to the above mass ratio and put them into a three-dimensional mixer and mix for 30 minutes to make drug fine powder, and take them out for later use;

[0044] Step 3: Preparation of adhesive: Weigh an appropriate amount of hypromellose according to the above mass ratio, add an appropriate amount of hot water to prepare an adhesive with a concentration of 2%, and set aside;

[0045] Step 4: Pill making: put the mixed drug fine powder into the feeding tank of the centrifugal pellet machine, put the ad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a cetirizine hydrochloride pseudo ephedrine sustained-release pellet. The cetirizine hydrochloride pseudo ephedrine sustained-release pellet comprises a medicated pellet body and a coating layer; the coating layer wraps the medicated pellet body; the medicated pellet body comprises 5 mg of cetirizine hydrochloride, 125 mg of pseudoephedrine hydrochloride, 80 mg of core pellets, 100-200 mg of fillers, 25-125 mg of lubricating agents and 5-50 mg of binding agents; the coating layer comprises 45-225 mg of Eudragit NE30D and 14-68 mg of talcum powder; the preparation method includes the steps that (1) material preparing; (2) mixing; (3) binding agent preparing; (4) pelleting; (5) coating material preparing, (6) coating; (7) filling; and (8) conducting aluminum plastic and obtaining end products. The cetirizine hydrochloride pseudo ephedrine sustained-release pellet is used for remitting nasal symptoms or non-nasal symptoms caused by perennial or seasonal anaphylactic rhinitis; a novel sustained release preparation and a novel pellet preparation are adopted, the treatment effect is stable, and the bioavailability is higher.

Description

technical field [0001] The invention belongs to the field of chemical drug sustained-release preparations, in particular to cetirizine hydrochloride pseudoephedrine sustained-release pellets and a preparation method thereof. Background technique [0002] Rhinitis refers to inflammation of the nasal mucosa and submucosal tissues. Manifested as congestion or edema, patients often have symptoms such as nasal congestion, runny nose, nasal itching, throat discomfort, coughing, etc. The thin liquid-like substance secreted by the nasal cavity is called nasal mucus or nasal secretion, and its function is to help remove dust and bacteria. to keep the lungs healthy. Under normal circumstances, the nasal mucus mixed with bacteria and dust is sucked into the throat and finally into the stomach. Because of the small amount of secretion, it generally does not attract people's attention. When there is inflammation in the nose, a large amount of nasal mucus can be secreted in the nasal ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/495A61K9/58A61P11/02A61K31/137
CPCA61K31/495A61K9/5031A61K9/5042A61K31/137
Inventor 马玉国
Owner HARBIN SHENGJI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com